8-K: Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results, Highlights Acclaim Cochlear Implant Progress

Envoy Medical announces its Q4 and full year 2024 financial results, along with a corporate update emphasizing progress in the pivotal clinical study for its Acclaim Cochlear Implant.

Summary

• Envoy Medical reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is making progress with its fully implanted Acclaim cochlear implant, with enrollment in the pivotal clinical trial going well.
• Six of the planned 10 participants in the first stage of the Pivotal Clinical Trial have been enrolled and implanted, with two activated.
• The company is also pursuing Medicare coverage for its Esteem implant through the Hearing Device Coverage Clarification Act.
• New CPT codes for fully implanted active middle ear implants, effective in July, could further reimbursement efforts for the Esteem implant.
• Net revenues decreased by $91 thousand for the year ended December 31, 2024, compared to the year ended December 31, 2023, due to a decrease in battery replacement sales.
• R&D expenses increased by $1.2 million for the year ended December 31, 2024, compared to the year ended December 31, 2023, due to increased headcount and contractors in engineering and clinical departments.
• As of December 31, 2024, cash and cash equivalents were approximately $5.5 million.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to progress in clinical trials and regulatory efforts, but tempered by revenue decline and net losses.

Positives

• FDA approval was received to initiate the pivotal clinical trial for the Acclaim cochlear implant.
• Enrollment in the pivotal clinical trial is progressing well, with six of ten participants enrolled and implanted in the first stage.
• There is continued advocacy for the Hearing Device Coverage Clarification Act, which could expand Medicare coverage for implanted active middle ear implants.
• New CPT codes have been approved for totally implantable active middle ear hearing implants, potentially opening new reimbursement opportunities.
• The company continues to increase its portfolio of patents and intellectual property.

Negatives

• Net revenues decreased by $91 thousand year-over-year due to supply chain limitations affecting battery replacement sales.
• The company reported a net loss attributable to common stockholders of $(27,973) thousand, or $(1.49) per share, for the year ended December 31, 2024.
• Cash and cash equivalents were approximately $5.5 million as of December 31, 2024.

Risks

• The forward-looking statements are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause actual results to differ significantly.
• These risks include unpredictability in the medical device industry, the regulatory process, and the clinical development process.
• Competition in the medical device industry and disruptions in relationships with suppliers are also potential risks.
• Changes in the need for capital and the availability of financing and capital to fund these needs could impact the company.
• Legal, regulatory and other proceedings could be costly and time-consuming to defend.

Future Outlook

The company expects to continue its pivotal clinical trial for the Acclaim CI and pursue Medicare coverage for the Esteem implant. They also anticipate new CPT codes for fully implanted active middle ear implants to further reimbursement efforts.

Management Comments

• Brent Lucas, CEO of Envoy Medical, commented: Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025.
• Brent Lucas, CEO of Envoy Medical, commented: Obtaining FDAs approval to begin our pivotal clinical trial for the fully implanted Acclaim cochlear implant was a milestone many years in the making, and we are very excited to report that enrollment is going extremely well.
• Brent Lucas, CEO of Envoy Medical, commented: We believe we have a special product and a great opportunity to change the hearing implant industry.

Industry Context

The announcement highlights Envoy Medical's efforts to innovate in the hearing health industry with fully implanted devices, positioning them as a potential disruptor in the cochlear implant and active middle ear implant markets. The push for Medicare coverage and new CPT codes reflects the industry's ongoing efforts to improve patient access to advanced hearing solutions.

Comparison to Industry Standards

• Envoy Medical's Acclaim CI aims to compete with established cochlear implant manufacturers like Cochlear Limited and MED-EL, offering a fully implanted solution.
• The Esteem FI-AMEI competes with traditional hearing aids and partially implanted devices from companies like Oticon Medical, offering a 24/7 hearing solution without external components.
• The company's focus on securing Medicare coverage aligns with industry efforts to expand access to hearing implants, similar to initiatives by other medical device companies.
• The development and approval of new CPT codes for fully implanted active middle ear implants is a significant step towards reimbursement parity with other hearing solutions.

Stakeholder Impact

• Shareholders: The financial results and progress of the Acclaim CI may impact shareholder value.
• Patients: Successful clinical trials and regulatory approvals could provide new hearing solutions for those with hearing loss.
• Employees: Increased headcount in engineering and clinical departments reflects investment in the company's future.
• Suppliers: Relationships with suppliers are important for the production of key components and materials.

Next Steps

• Continue enrollment in the pivotal clinical trial for the Acclaim CI.
• Pursue the bipartisan Hearing Device Coverage Classification Act.
• Work towards reimbursement for the Esteem implant with the new CPT codes.

Key Dates

Keywords

Acclaim Cochlear Implant, Esteem Implant, Hearing Device Coverage Clarification Act, Cochlear Implant, Hearing Implant, Envoy Medical, Financial Results